SKBI / Skystar Bio-Pharmaceutical Company - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Skystar Bio-Pharmaceutical NT 10-Q

NT 10-Q 1 v453150nt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-34394 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10D ¨ Form N-SAR ¨ Form N-CSR CUSIP NUMBER 830884102 For Period Ended: September 30, 2016 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ T

Skystar Bio-Pharmaceutical NT 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-34394 CUSIP NUMBER 830884102 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transiti

Skystar Bio-Pharmaceutical FORM NT 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-34394 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10D ¨ Form N-SAR ¨ Form N-CSR CUSIP NUMBER 830884102 For Period Ended: March 31, 2016 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transit

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No.

PRIVATE & CONFIDENTIAL

EX-7.2 2 v438228ex7-2.htm EXHIBIT 7.2 Exhibit 7.2 PRIVATE & CONFIDENTIAL Our Ref: SCH1623/SS/KK/A18/CH0589/16 April 28, 2016 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 USA Ladies and Gentlemen: We have read the statements regarding our firm contained in Items 4.01 and 4.02 of Form 8-K of Skystar Bio-Pharmaceutical Company dated and

Skystar Bio-Pharmaceutical FORM 12B-25

NT 10-K 1 v43685912b25.htm FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 0001283843 NOTIFICATION OF LATE FILING CUSIPNUMBER 29101U407 (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2016 SKYSTAR BIO-PHARMACEUTICAL COMPANY (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 001-34394 33-0901534 (Commission File Number) (IRS Employer Identification No.

PRIVATE & CONFIDENTIAL

Exhibit 7.1 PRIVATE & CONFIDENTIAL Our Ref: SCH1623/SS/KK/A18/CH0586/16 March 31, 2016 Management and the Audit Committee Skystar Bio-Pharmaceutical Company 4/F Building B Chuangye Square, No. 48 Keji Road, Gaoxin District, Xi?an Shaanxi Province People?s Republic of China Attn: Mr. Wei bing Lu, Chief Executive Officer Mr. Mark Chen, Chairman, Audit Committee Mr. R. Scott Cramer, Director Mr. Bing

SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES DELISTING FROM NASDAQ

Exhibit 99.1 SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES DELISTING FROM NASDAQ Xi?an, China, December 18, 2015 ? Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on December 17, 2015, Skystar Bio-Pharmaceutical Company (the ?Company?) received notification from The Nas

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2015 SKYSTAR BIO-PHARMACEUTICAL COMPANY (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 001-34394 33-0901534 (Commission File Number) (IRS Employer Identification No.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 17, 2015 SKYSTAR BIO-PHARMACEUTICAL COMPANY (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporation) 001-34394 33-0901534 (Commission File Number) (IRS Employer Identification No.

SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION LETTER

EX-99.1 2 v425312ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION LETTER Xi’an, China, November 19, 2015 – Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on November 17, 2015, it received a letter from NA

Skystar Bio-Pharmaceutical NT 10-Q

NT 10-Q 1 v424899nt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 333-68008 CUSIP NUMBER [] (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2015 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transiti

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events

8-K 1 v4227178k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2015 SKYSTAR BIO-PHARMACEUTICAL COMPANY (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incorporat

SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION LETTER

EX-99.1 2 v422717ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION LETTER Xi’an, China, October 23, 2015 – Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on October 20, 2015 it received a letter from

SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NON-COMPLIANCE LETTER DUE TO DELAY IN FILING FORM 10-Q

Exhibit 99.1 SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NON-COMPLIANCE LETTER DUE TO DELAY IN FILING FORM 10-Q Xi?an, China, August 25, 2015 ? Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the ?Company?), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on August 19, 2015, the Company rece

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

8-K 1 v4189328k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 19, 2015 SKYSTAR BIO-PHARMACEUTICAL COMPANY (Exact Name of Registrant as Specified in Its Charter) Nevada (State or Other Jurisdiction of Incor

Skystar Bio-Pharmaceutical NT 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER NOTIFICATION OF LATE FILING 001-34394 CUSIP NUMBER [] (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Repo

SKBI / Skystar Bio-Pharmaceutical Company / SJ STRATEGIC INVESTMENTS LLC - SC 13D/A Activist Investment

SC 13D/A 1 d936015dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) (Amendment No. 6) Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class Of Securities) 830884102 (CUSIP Number) John M.

By Electronic Delivery to: [email protected]; [email protected]; [email protected] May 21, 2015 Mr. Bing Mei Chief Financial Officer Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No.

Exhibit 99.2 By Electronic Delivery to: [email protected]; [email protected]; [email protected] May 21, 2015 Mr. Bing Mei Chief Financial Officer Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No. 48 Keji Road Gaoxin District, Xi?an Shaanxi Province, P.R. China Re: Skystar Bio-Pharmaceutical Company (the ?Company?) Nasdaq Symbol: SK

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events

8-K 1 v4114918k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2015 Skystar Bio-Pharmaceutical Company (Exact name of registrant as specified in its charter) Nevada 001-34394 33-0901534 (State or other jurisdict

SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NON-COMPLIANCE LETTER DUE TO DELAY IN FILING FORM 10-Q

EX-99.1 2 v411491ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NON-COMPLIANCE LETTER DUE TO DELAY IN FILING FORM 10-Q Xi’an, China, May 22, 2015 – Skystar Bio-Pharmaceutical Company (Nasdaq: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company re

Skystar Bio-Pharmaceutical NT 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34394 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: March 31, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NON-COMPLIANCE LETTER DUE TO DELAY IN FILING FORM 10-K

Exhibit 99.1 SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NON-COMPLIANCE LETTER DUE TO DELAY IN FILING FORM 10-K Xi?an, China, April 15, 2015 ? Skystar Bio-Pharmaceutical Company (Nasdaq: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq S

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events

8-K 1 v4074118k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2015 Skystar Bio-Pharmaceutical Company (Exact name of registrant as specified in its charter) Nevada 001-34394 33-0901534 (State or other jurisdi

By Electronic Delivery to: [email protected]; [email protected]; [email protected]

Exhibit 99.2 805 King Farm Blvd. Rockville, MD 20850 / USA Nasdaq.com By Electronic Delivery to: [email protected]; [email protected]; [email protected] April 15, 2015 Mr. Bing Mei Chief Financial Officer Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No. 48 Keji Road Gaoxin District, Xi?an Shaanxi Province, P.R. China Re: Skystar B

Skystar Bio-Pharmaceutical FORM NT 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34394 (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: December 31, 2014 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

SKBI / Skystar Bio-Pharmaceutical Company / SJ STRATEGIC INVESTMENTS LLC - SC 13D/A Activist Investment

SC 13D/A 1 d864930dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) (Amendment No. 5) Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class Of Securities) 830884102 (CUSIP Number) John M.

SKBI / Skystar Bio-Pharmaceutical Company / GREGORY JOHN M - NONE Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 04 )* SKYSTAR BIO-PHARMACEUTICAL CO (Name of Issuer) Common Stock (Title of Class of Securities) 830884102 (CUSIP Number) John M. Gregory, SJ Strategic Investments, LLC 340 MARTIN LUTHER KING, JR. BLVD., Suite 200 BRISTOL, Tennessee 37620 Phone : (423) 989-8

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2014 Skystar Bio-Pharmaceutical Company (Exact name of registrant as specified in its charter) Nevada 001-34394 33-0901534 (State or other jurisdiction (Commission File No.

Skystar Bio-Pharmaceutical FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2014 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .

EMPLOYMENT AGREEMENT

Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is dated as of July 29, 2014 and by and between Bing Mei, an individual (?Executive?), and Skystar Bio-Pharmaceutical Company, a Nevada corporation having its principal office at 4/F Building B, Chuangye Square, No. 48 Keji Road, Gaoxin District, Xian, Shaanxi Province, People?s Republic of China (the ?Company?). WHEREA

SKBI / Skystar Bio-Pharmaceutical Company DEF 14A - - DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

Skystar Bio-Pharmaceutical 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2014 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to .

EX-3.1

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

8-K 1 v3842698k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2014 Skystar Bio-Pharmaceutical Company (Exact name of registrant as specified in its charter) Nevada 001-34394 33-0901534 (State or other jurisdic

430 Park Avenue | New York, New York 10022 | 212.356.0500 | www.hcwco.com Member: FINRA/SIPC

July 14, 2014 STRICTLY CONFIDENTIAL Weibing Lu Chairman of the Board Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No.

COMMON STOCK PURCHASE WARRANT skystar bio-pharmaceutical company

EXHIBIT A COMMON STOCK PURCHASE WARRANT skystar bio-pharmaceutical company Warrant Shares: Initial Exercise Date: January , 2015 Issue Date: July , 2014 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2014 Skystar Bio-Pharmaceutical Company (Exact name of registrant as specified in its charter) Nevada 001-34394 33-0901534 (State or other jurisdiction (Commission File No.

Skystar Bio-Pharmaceutical Company 790,514 Shares of Common Stock 1,000 Shares of Series C Preferred Stock (and 197,629 Shares Underlying the Series C Preferred Stock) Warrants to Purchase 247,036 Shares of Common Stock (and 247,036 Shares of Common

Filed Pursuant to Rule 424(b)(5) Registration No. 333-192657 Prospectus Skystar Bio-Pharmaceutical Company 790,514 Shares of Common Stock 1,000 Shares of Series C Preferred Stock (and 197,629 Shares Underlying the Series C Preferred Stock) Warrants to Purchase 247,036 Shares of Common Stock (and 247,036 Shares of Common Stock Issuable Upon Exercise of Warrants) We are offering 790,514 shares of co

SECURITIES PURCHASE AGREEMENT

SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 14, 2014, between Skystar Bio-Pharmaceutical Company, a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

SKBI / Skystar Bio-Pharmaceutical Company / SJ STRATEGIC INVESTMENTS LLC - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) (Amendment No. 3) Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class Of Securities) 830884102 (CUSIP Number) John M. Gregory SJ Strategic Investments, LLC 3

CONSULTING SERVICES AGREEMENT

EX-10.3 2 v378239ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 CONSULTING SERVICES AGREEMENT This CONSULTING SERVICES AGREEMENT (this “Agreement”), is dated as of March 10, 2014, 2013, by and between Skystar Bio-Pharmaceutical Company, a Nevada corporation (the “Company”), and R. Scott Cramer, an individual, whose address is 800 N. Maitland Ave., Suite 204, Maitland, Fl 32751 (the “Consultant”). The Compan

Skystar Bio-Pharmaceutical FORM 10-Q (Quarterly Report)

10-Q 1 v37823910q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2014 or ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number

Other Events

8-K 1 v3748708k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2014 Skystar Bio-Pharmaceutical Company (Exact name of registrant as specified in its charter) Nevada 001-34394 33-0901534 (State or other jurisdi

SKBI / Skystar Bio-Pharmaceutical Company / SJ STRATEGIC INVESTMENTS LLC - SC 13D/A Activist Investment

SC 13D/A 1 d711262dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) (Amendment No. 2) Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class Of Securities) 830884102 (CUSIP Number) John M.

SKBI / Skystar Bio-Pharmaceutical Company / SJ STRATEGIC INVESTMENTS LLC - SC 13D/A Activist Investment

SC 13D/A 1 d703942dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) (Amendment No. 1) Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class Of Securities) 830884102 (CUSIP Number) John M.

Skystar Bio-Pharmaceutical FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34394 SKYSTAR BIO-PHARMACEUTICA

SKBI / Skystar Bio-Pharmaceutical Company / SJ STRATEGIC INVESTMENTS LLC - SKYSTAR BIO-PHARMACEUTICAL COMPANY 13D MARCH 20, 2014 Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class Of Securities) 830884102 (CUSIP Number) James M. Gregory SJ Strategic Investments, LLC 340 Martin Luther

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2014 Skystar Bio-Pharmaceutical Company (Exact name of registrant as specified in its charter) Nevada 001-34394 33-0901534 (State or Other Jurisdiction (Commission (I.R.S. E

EMPLOYMENT AGREEMENT

EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is dated as of July 29, 2013 and by and between Bing Mei, an individual (“Executive”), and Skystar Bio-Pharmaceutical Company, a Nevada corporation having its principal office at 4/F Building B, Chuangye Square, No.

EMPLOYMENT AGREEMENT

EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “ Agreement ”), dated as of May 5, 2013 by and between Weibing Lu, residing at Suite F2-1002, Maple New City, Gaoxin District, Xi’an, Shaanxi Province, China (“ Executive ”), and Skystar Bio-Pharmaceutical Company a Nevada corporation having its principal office at 4/F Building B Chuangye Square, No.

- FORM S-3/A

As filed with the Securities and Exchange Commission on December 16, 2013 Registration No.

SKYSTAR BIO-PHARMACEUTICAL COMPANY AS TRUSTEE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS

EX-4.1 2 v355137ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 SKYSTAR BIO-PHARMACEUTICAL COMPANY TO AS TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.1 DEFINITIONS 1 SECTION 1.2 COMPLIANCE CERTIFICATES AND OPINIONS 8 SECTION 1.3 FORM OF DOCUMENTS DELIVERED TO TRUSTEE 8 SECTION 1.4 ACTS OF HOLDERS; R

SKYSTAR BIO-PHARMACEUTICAL COMPANY AS TRUSTEE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS

Exhibit 4.2 SKYSTAR BIO-PHARMACEUTICAL COMPANY TO AS TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.1 DEFINITIONS 1 SECTION 1.2 COMPLIANCE CERTIFICATES AND OPINIONS 9 SECTION 1.3 FORM OF DOCUMENTS DELIVERED TO TRUSTEE 10 SECTION 1.4 ACTS OF HOLDERS; RECORD DATES 10 SECTION 1.5 NOTI

- FORM S-3

As filed with the Securities and Exchange Commission on December 4, 2013 Registration No.

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

8-K 1 v3584198k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2013 Skystar Bio-Pharmaceutical Company (Exact name of registrant as specified in its charter) Nevada 001-34394 33-0901534 (State or Other Jur

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant S Filed by a Party other than the Registrant £ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

SKBI / Skystar Bio-Pharmaceutical Company / RENN Universal Growth Investment Trust - 13 G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.) 8 Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class of Securities) 830884102 (CUSIP Number) 9/23/2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

SKBI / Skystar Bio-Pharmaceutical Company / RENN Universal Growth Investment Trust - 13 G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.) 7 Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class of Securities) 830884102 (CUSIP Number) 9/13/2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

SKBI / Skystar Bio-Pharmaceutical Company / RENN Universal Growth Investment Trust - 13 G/A Passive Investment

SC 13G/A 1 skbi13ga09132013.htm 13 G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.) 6 Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class of Securities) 830884102 (CUSIP Number) 9/4/2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to

SKBI / Skystar Bio-Pharmaceutical Company / RENN Universal Growth Investment Trust - 13 G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.) 5 Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class of Securities) 830884102 (CUSIP Number) 8/22/2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

SKBI / Skystar Bio-Pharmaceutical Company / RENN Universal Growth Investment Trust - SKBI 13 G/A Passive Investment

SC 13G/A 1 skbi13garusgit.htm SKBI 13 G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.) 4 Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class of Securities) 830884102 (CUSIP Number) 8/15/2013 (Date of Event which Requires Filing of this Statement) Check the appropriate bo

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

8-K 1 v3266638k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2012 Skystar Bio-Pharmaceutical Company (Exact name of registrant as specified in its charter) Nevada 001-34394 33-0901534 (State or Other Jurisdic

- SCHEDULE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2012 Skystar Bio-Pharmaceutical Company (Exact name of registrant as specified in its charter) Nevada 001-34394 33-0901534 (State or Other Jurisdiction (Commission (I.R.S. Em

Crowe Horwath LLP

Crowe Horwath LLP Independent Member Crowe Horwath International July 6, 2012 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, N.

- S-8

Registration No. 333- As filed with the Securities and Exchange Commission on April 27, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Skystar Bio-Pharmaceutical Company (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 33-0901534

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

8-K 1 v3109328k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2012 Skystar Bio-Pharmaceutical Company (Exact name of registrant as specified in its charter) Nevada 001-34394 33-0901534 (State or Other Juris

- FORM DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2012 Skystar Bio-Pharmaceutical Company (Exact name of registrant as specified in its charter) Nevada 001-34394 33-0901534 (State or Other Jurisdiction (Commission (I.R.S.